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OmalizumabThe dosing level and frequency of omalizumab are guided by a dosing table based on total serum immu-
noglobulin E (IgE) and bodyweight. Using a validated, mathematical simulation model (based on concen-
tration data from 8 studies), we evaluated the impact of a revised omalizumab dosing table (every
4 weeks dosing regimen) on the pharmacokinetic and pharmacodynamic proﬁles of free and total IgE.
Safety analysis, in patients with high levels of exposure to omalizumab, was done using data from the
clinical and post-marketing databases. The model accurately predicted observed omalizumab, free and
total IgE concentrations. After reaching steady-state, the average increase in exposure was 10%, even
for patients with the highest concentrations at the upper 97.5th percentile. Free IgE suppression slightly
increased in the initial phase, and slightly reduced at the trough of the dosing cycle, but average suppres-
sion remained similar for both regimens. The safety proﬁle of omalizumab was similar for patients
receiving higher or lower doses. Thus, doubling the dose of omalizumab, in a subset of patients receiving
225–300 mg of omalizumab (every 2 weeks dosing regimen) can efﬁciently suppress free IgE without
compromising safety or efﬁcacy.
 2014 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Omalizumab is a humanized anti-immunoglobulin E (IgE)
monoclonal antibody licensed in the European Union (EU) as an
add-on therapy for adults, adolescents and children (ageP6 years)
with inadequately-controlled severe allergic (IgE-mediated)
asthma, and in the United States for adults and adolescents
(ageP12 years) with moderate-to-severe allergic asthma (EMA
Xolair Summary of product information, 2013; US FDA Xolair
prescribing Information, 2013; Chipps et al., 2012). Omalizumab
is administered by subcutaneous (sc) injection every 2 weeks
(q2w) or 4 weeks (q4w), with the exact dose being individualized
on the basis of baseline serum IgE measurements and bodyweight
(Fig. 1). The aim of the omalizumab dosing table is to prescribe reg-
imens to achieve an average serum free IgE of 25 ng/mL (with 95%
patients below 50 ng/mL), a level associated with clinical improve-ment (EMA Xolair Summary of product information, 2013; US
FDA Xolair prescribing Information, 2013; Hochhaus et al.,
2003). In addition, the dosing table also acts as a reference support-
ing the rational prescribing of omalizumab, avoiding overdosing
smaller or underdosing larger bodyweight patients, whilst admin-
istering a dose in proportion to the amount of baseline total serum
IgE, in the body to be bound and hence neutralized, in the body.
Omalizumab must be administered under medical supervision
and is usually given in a hospital or a physician’s ofﬁce. This
requirement can be inconvenient for working patients, those in
school, or long distance travelers. Observing that 600 mg doses
had been recently approved in EU (2013), physicians in Israel asked
whether it would be possible to revise the dosing table, increasing
the time interval from every 2 weeks to every 4 weeks for some
cells, increasing the dose from 225 or 300 mg to 450 or 600 mg,
respectively, at each visit (Fig. 1). We investigated whether such
a dosing table revision (DTR) would be possible without compro-
mising safety or tolerability or losing efﬁcacy by using a pharmaco-
kinetic and pharmacodynamic (PK–PD) modeling and simulation
approach. The logic steps were thus: (i) describe and characterize
omalizumab, free and total IgE concentration-time proﬁles for a
population of patients with asthma using a mathematical model;
(ii) check that, when simulating from this PK–PD model
P.J. Lowe et al. / Regulatory Toxicology and Pharmacology 71 (2015) 68–77 69(as opposed to ﬁtting data), it had the ability to predict PK and free
IgE responses; (iii) develop and visualize a relationship between
the omalizumab-induced suppression of free IgE and the signs
and symptoms of asthma; (iv) if the model could be shown to be
predictive, then using simulations, show the consequences of
changing the administration from every 2 weeks to every 4 weeks;
and, ﬁnally, for safety, (v) check that the increased peak
omalizumab concentrations, that patients would experience by
administering 600 mg doses, would not lead to an increase in
adverse reactions by surveying the extensive safety database,
concentrating especially on patients who had experienced high
levels of peak exposure to omalizumab.
2. Methods
2.1. Data
PK–PDmodels generally start from relatively small datasets and
then evolve over the years as clinical development progresses;
additional data is then included and more is learned about the
compound. For the omalizumab–IgE model, it started with sin-
gle-dose data in atopic but otherwise healthy volunteers (Meno-
Tetang and Lowe, 2005) through the addition of two Japanese
and three Caucasian studies (Hayashi et al., 2007), then further
intermediate incarnations (Lowe et al., 2009; Slavin et al., 2009)
to the form used for the expansion of the EU dosing table in Janu-
ary 2010 (EMA Xolair Summary of product information, 2013).
For the DTR, the PK–PD model referenced data from 9 studies
(Busse et al., 2001; Holgate et al., 2004; Humbert et al., 2005;
Kornmann et al., 2014; Lanier et al., 2009; Milgrom et al., 2001;
Riviere et al., 2011; Soler et al., 2001; Zielen et al., 2013).
Four phase III studies in adults contribute most of the data: two
7-month, randomized, double-blind, parallel-group, placebo-con-
trolled, multicenter studies with 5-month blinded extension peri-
ods in adolescents and adults with moderate-to-severe allergicBaseline
IgE IU/mL
B
20—25 >25—30 >30—40 >40—50 >50—
≥30—100 75 75 75 150 15
>100—200 150 150 150 300 30
>200—300 150 150 225 300 30
>300—400 225 225 300 225 22
>400—500 225 300 225 225 30
>500—600 300 300 225 300 30
>600—700 300 225 225 300 37
>700—800 225 225 300 375 45
>800—900 225 225 300 375 45
>900—1000 225 300 375 450 52
>1000—1100 300 300 375 450 60
>1100—1200 300 300 450 525 60
>1200—1300 300 375 450 525
>1300—1500 300 375 525 600
Fig. 1. Omalizumab dosing table wasthma requiring daily treatment with inhaled corticosteroids
(ICS) (Busse et al., 2001; Soler et al., 2001); a 32-week, randomized,
double-blind, parallel-group, placebo-controlled, multicenter pilot
trial to assess corticosteroid reduction in adolescents and adults
with severe allergic asthma requiring daily treatment with high-
dose ICS, with or without oral corticosteroids (Holgate et al.,
2004); and INNOVATE, a 28-week treatment, 16-week follow-up,
randomized, double-blind, placebo controlled study in patients
with inadequately-controlled severe persistent allergic asthma
(Humbert et al., 2005).
Data from two pediatric (6–12 years) pivotal phase III studies
also contributed to the model: a 7-month double-blind, random-
ized, placebo-controlled trial that assessed the safety and efﬁcacy
of omalizumab in children with allergic asthma requiring daily
treatment with ICS (Milgrom et al., 2001), and a 1-year study with
moderate-to-severe, persistent, inadequately-controlled allergic
asthma (Lanier et al., 2009).
In addition, two clinical pharmacology studies used the
expanded dosing regimen (for patients with baseline IgE levels
>100 and 61500 IU/mL, requiring omalizumab by sc injection
q2w). These were: (i) a randomized, double-blind, placebo-con-
trolled study demonstrating the protective effects of omalizumab
against allergen-induced bronchoconstriction in patients (aged
18–65 years) with allergic asthma and baseline IgE up to
2000 IU/mL (Zielen et al., 2013); and (ii) a multicenter, open-label,
parallel-group study evaluating omalizumab at high doses in
patients (aged 18–55 years) with IgE/bodyweight combinations
outside the initially approved dosing regimen (Kornmann et al.,
2014) . Finally, a single-dose parallel-group bioequivalence study
investigated the use of omalizumab (150 and 300 mg sc) in atopic
(total IgE above normal levels [30–300 IU/mL]) but otherwise
healthy volunteers (Riviere et al., 2011).
In all studies, omalizumab was administered by sc injection
q2w or q4w according to patients’ pre-treatment bodyweight
and baseline IgE levels using either the earlier US dosing table orody weight
60 >60—70 >70—80 >80—90 >90—125 >125—150
0 150 150 150 300 300
0 300 300 300 225 300
0 225 225 225 300 375
5 225 300 300 450 525
0 300 375 375 525 600
0 375 375 450 600
5 450 525 525
0 450 525 600
0 525 600
5 600 Do not administer
0
0 treatment every 4 weeks
could be switched to q4wk
mg/kg dose too high to switch
Too many injections to switch
ith cells which were updated.
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ies were approved by Institutional Review Boards and all patients
gave informed written consent. The studies were conducted in
accordance with the Declaration of Helsinki and Good Clinical
Practice guidelines.
2.2. Model used for simulation
The nonlinearmixed-effectsmodel, which speciﬁes omalizumab
binding and capture of IgE to form complexes and thereby suppres-
sion of free unbound IgE, has been described previously (Lowe and
Renard, 2011). This PK–PD model included parameters for the
clearances of omalizumab and IgE, volumes of distribution for oma-
lizumab, IgE and the IgG–IgE complexes, rates for IgE synthesis
(daily production) and drug absorption and, ﬁnally, an in vivo
apparent equilibrium binding constant, KDapp, the omalizumab con-
centration for 50% binding of IgE under idealized conditions when
IgE levels are very low (the equivalent of KM for enzyme reactions).
The binding equations in themodel use KDapp togetherwith the input
and output rates of omalizumab and IgE to calculate target capture
(occupancy) for all IgE levels at all time-points.
The only changes to the parameters from the dosing table
expansion variation (EMA Xolair Summary of product
information, 2013) were to update the population mean and
inter-individual variances for drug absorption and the volume of
the omalizumab–IgE complexes, based on improved estimation
methods, which could be used with richly sampled PK and IgE data
in the ﬁrst days post-dose in two bioequivalence studies; these val-
ues were reported by Lowe and Renard (2011).
2.3. Predictive ability of the model
The model was checked for its predictive ability, focusing on
maximum and pre-dose trough omalizumab concentrations andFig. 2. Illustration of omalizumab total and free IgE data from one phase III study. Exam
every 4 weeks (b) to samples collected from 2 individual patients showing model ﬁts
predictions for free IgE in all omalizumab-treated patients from the INNOVATE study (c
permission from (Slavin et al., 2009).trough concentrations of free IgE. This was achieved by creating
simulations and overlaying data from clinical studies for:
a) Omalizumab and free IgE concentrations after single admin-
istrations for atopic healthy individuals enrolled in the bio-
equivalence study (Riviere et al., 2011).
b) Omalizumab and free IgE concentrations in patients with
allergic asthma after multiple administrations q2w and q4w.
To be considered valid for subsequent predictions, the model
had to be able to accurately simulate the median (50th percentile)
and the degree of random variation between patients’ data, as rep-
resented by the upper 97.5th and lower 2.5th percentile responses.
An alternative weighted residuals method was also used to
assess and conﬁrm predictivity (Boeckmann et al., 2011). In this,
deviations of observations from predictions were examined over
time and from low to high concentrations of omalizumab, free
and total IgE. This diagnostic method to assess the ‘‘quality of ﬁt’’
takes account of ﬁxed patient factors (covariates) and has the abil-
ity to provide simple plots even when patients receive different
doses and have samples taken at different times. To take account
of random variation between patients, the deviations were normal-
ized by the variance estimates to a standard deviation scale; 95% of
the data should then be within ±2 standard deviations of the
prediction.
2.4. Simulations for the revised dosing regimen
Following validation of its predictive ability, the model was
used to simulate the proposed every 4 weeks dosing regimens for
the areas of the dosing table to be revised. This revision would
apply to patients currently on doses of 225 and 300 mg q2w. Sim-
ulations for concentration–time proﬁles of omalizumab and free
IgE were performed using the Berkeley Madonna™ softwareple ﬁts of the model for a single 300 mg dose (a) and multiple 150 mg doses given
for each patient’s plasma omalizumab, total IgE, and free IgE. Individual patient
) Omalizumab concentrations present a similar (mirrored) image. Reproduced with
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highlighted in Fig. 1, simulations were performed for 1000 virtual
patients with uniform distributions of bodyweight and baseline IgE
within the dimensions of each cell. Simulations of omalizumab and
free IgE geometric mean, lower (2.5th) and upper (97.5th) percen-
tiles of the 95% range were compared for both the original and the
revised dosing regimens.
2.5. Safety
The safety of high doses of omalizumab was assessed based on
pooled data from studies in which patients had received at least
one daily dose ofP600 mg of omalizumab at any time. Five studies
were identiﬁed (Kornmann et al., 2014; Milgrom et al., 2001; Saini
et al., 1999, 2011; Zielen et al., 2013), and their data pooled to con-
ﬁrm the safety proﬁle of high dose omalizumab, especially in terms
of adverse events (AEs). Additionally, a cumulative search with a
cut-off date of 30 June 2011 was conducted in the global postmar-
keting safety database to identify patients who had received
P900 mg/month of omalizumab.
3. Results
3.1. Predictive ability of the model
The omalizumab–IgE binding model has been shown to have
the ability to ﬁt patient data for serum concentrations of the drug
and for free and total IgE (Fig. 2). This model applies to single and
multiple doses, for frequently or sparsely sampled individuals. Pre-
vious reports have shown that the model can predict the timeFig. 3. Prediction-corrected visual prediction checks for omalizumab and free IgE. The da
patients, i.e. >92 days from the start of treatment (Bergstrand et al., 2011). The symbols r
of the data; the bands are the 95% prediction intervals for the speciﬁed percentiles fr
important patient factors, such as bodyweight and baseline IgE and other factors, suchcourse of data not used for its creation (Hayashi et al., 2007) and
can predict both the median distribution of free IgE at steady-state
troughs (Lowe et al., 2009). However, to revise the dosing table by
doubling the dose and halving the administration frequency, peak
concentrations of omalizumab became a point of focus. To provide
assurance that the omalizumab–IgE model was accurately predic-
tive for the omalizumab maximum concentration (Cmax) as well as
trough concentrations for the many different doses, regimens,
baseline IgE and bodyweight combinations, prediction-corrected
visual prediction checks were created (Fig. 3). In these it can be
seen that there were no notable deviations between observed data
and the model predictions for omalizumab Cmax, or the trough con-
centrations 14 or 28 days post-dose. The model was also predictive
for maximum and trough free IgE concentrations, and the random
distribution of responses, given that the observed and predicted
2.5th and 97.5th percentiles matched well. Random variation in
the single dose data was somewhat overestimated; however, these
data were atopic but otherwise healthy volunteers, not asthma
patients, so could be expected to be more homogeneous. The alter-
native method of assessing predictivity using weighted residuals
showed that the distribution of errors between observations and
predictions was centered on zero deviation (Fig. 4). This was true
for Cmax between 2 and 13 days, for the trough samples at around
14 days for every 2 weeks dosing regimen and 28 days for every
4 weeks dosing regimen, and for both omalizumab and free IgE.
3.2. Simulations for revised dosing regimen
Given that the prediction veriﬁcation suggested the oma-
lizumab–IgE model to be predictive of maximum change andta and simulations are plotted as time post-dose, being steady-state for the asthma
epresent the data; the lines the 2.5th, 50th (median, red line) and 97.5th percentiles
om model simulations. The simulations and data were ‘prediction corrected’, i.e.
as the dose, had been taken into account.
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bodyweights and baseline IgE values, the implications of changes
in dose and regimen, deﬁned by the term posology, could be
explored through simulation from the model. Fig. 5 shows the
results for omalizumab, Fig. 6 for free IgE. To illustrate the result,
a single cell is taken – that with the highest concentrations. In
the cell for 40–50 kg bodyweight and 500–600 IU/mL baseline
IgE, the original dose was 300 mg q2w, revised to 600 mg q4w.
The geometric mean maximum omalizumab concentration at
steady-state was about 165 lg/mL for the q2w regimen and
195 lg/mL for the corresponding q4w. The upper 97.5th percen-
tile, corresponding to only 2.5% of patients, was at just over 310 lg/
mL for q2w, 360 lg/mL for q4w, an increase of only 15%. Across all
revised cells, the upper 97.5th percentile Cmax increased by, on
average, 10% (minimum 4%, maximum 20%).
Examination of the free IgE responses demonstrated that the
algorithm that forms the basis for the dosing table, P0.016 mg/
kg bodyweight per IU/mL of baseline IgE per month, enabled all
patients to achieve similar free IgE suppression irrespective of their
bodyweight or baseline IgE (Fig. 6). For the revised posology, aTime post−dose (days)
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Fig. 4. Predictivity for omalizumab assessed by weighted residuals. The weighted residu
(vertical). The regimen designations are 0 for single dose (green), 2 for q2w (red) and 4 f
maximum concentration (Cmax) between 1 and 13 days (b) omalizumab minimum conce
q2w (c) free IgE Cmin between 1 and 13 days (d) free IgE Cmax or trough pre-dose or 22–slight increase in free IgE suppression was anticipated in the ﬁrst
part of the dosing cycle, with correspondingly lower suppression
at trough. However, the average suppression remained the same
for both regimens, with trough concentrations predicted to remain
below the target of 50 ng/mL, for 95% of the population.
Given that free IgE correlates with changes in the total symp-
tom score, peak expiratory ﬂow and rescue medication use (Lowe
et al., 2009), one should be assured that all ranges of baseline IgE
and bodyweight should respond to omalizumab. Regarding the
question of whether the change in regimen from q2w to q4w is
likely to change the clinical response due to the more pulsatile nat-
ure of the free IgE time proﬁle, this is considered unlikely. The clin-
ical response to omalizumab develops slowly over the course of
several months (Slavin et al., 2009), perhaps even after a year of
treatment (Dal Negro et al., 2011). This would correlate well with
the long lifetime of IgE secreting plasma cells, which ‘‘will take sev-
eral weeks or several months (some say more than 1 year) to die
off’’ (Lanier et al., 2009). The slow turnover of biosystem compo-
nents such as mast or plasma cells would act to smooth out ﬂuctu-
ations from the original dosing. To illustrate this, three simulationsTime post−dose (days)
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ntration (Cmin) or trough pre-dose or 22–35 days post-last dose for q4w, 10–18 days
35 days post-last dose for q4w, 10–18 days q2w.
Fig. 5. Steady-state 4-week interval omalizumab simulations for revised cells of the dosing table. The pairs of lines (black lines for the q2w regimen with two dosing cycles
and grey lines for the q4w regimen) represent, from the top, upper 97.5th percentiles, geometric means, and 2.5th percentiles.
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omalizumab, free IgE, or cellular high afﬁnity IgE receptors (FceRI)
drives the turnover of factors responsible for the production of
symptoms (Fig. 7). Comparing the same monthly dose given either
every 2 or 4 weeks, one can see that, although in theory there could
be very minor ﬂuctuations in response, in practice, given random
day-to-day variation, there would likely be no signiﬁcant differ-
ence in the signs and symptoms of asthma. The longer it takes
for a clinical response to build, the less the inﬂuence of changes
in regimen.
3.3. Safety
Using the pooled data, patients receiving P600 mg of oma-
lizumab were compared with all other patients (Kornmann et al.,
2014; Milgrom et al., 2001; Saini et al., 1999, 2011; Zielen et al.,
2013). A total of 87 out of 404 patients from the 5 studies analyzed
were identiﬁed as having receivedP600 mg of omalizumab.
Although incidences of oral herpes and urticaria were slightly
higher in patients treated with higher dose of omalizumab com-pared to the standard dose ([oral herpes: 5/87 versus 6/317; 95%
CI: –0.013, 0.090], [urticaria: 8/87 versus 10/317; 95% CI: –0.003,
0.124]), the differences were not signiﬁcant based on the 95% CI
for the difference between proportions. There were no cases of
thrombocytopenia, arterial thrombotic events, Churg-Strauss syn-
drome or parasitic infections in patients receivingP600 mg of
omalizumab. One case of malignant melanoma was detected in a
patient who receivedP600 mg of omalizumab, but was not sus-
pected to be related to omalizumab. A single moderate anaphylac-
toid reaction was also observed in a patient who received an
intravenous dose of 1150 mg omalizumab. There was no evidence
of unexpected adverse events; all the adverse events seen in this
pooled analysis were consistent with the known safety proﬁle of
omalizumab.
Clinical data from an empirical subset of 100 patients with the
highest concentrations of omalizumab (all above the upper limit
predicted to occur with the revised dosing regimen) showed a sim-
ilar safety proﬁle to that of the rest of the treated population. In the
omalizumab postmarketing database, 129 patients were identiﬁed
who had received multiple doses of omalizumab cumulative to
Fig. 6. Steady-state 4-week-interval free IgE simulations for revised cells. The pairs of lines (black lines for the q2w regimen with two dosing cycles and grey lines for the q4w
regimen) represent, from the top, upper 97.5th percentiles, geometric means, and 2.5th percentiles.
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307 events (in 70 patients) were identiﬁed as serious and 236
events (in 89 patients) were classiﬁed as non-serious. The distribu-
tion of adverse events in these patients was consistent with that
seen at lower omalizumab doses. No increase in the incidence of
anaphylaxis was seen.
4. Discussion
Asthma is a chronic inﬂammatory disorder of the airways.
When uncontrolled, asthma can be a cause of substantial morbid-
ity and mortality; it is also economically burdensome (Croisant,
2014). In the case of omalizumab prescribed to patients with
uncontrolled severe asthma, frequent attendance for injections
interferes with their personal and work life and may be associated
with indirect expenses such as extra costs for travel or income lost
from work to attend an injection clinic. Reducing the frequency of
administration of omalizumab to every 4 weeks, where possible,
reduces patient burden and costs. This less burdensome treatment
regimen for eligible patients may aid persistence with treatment,thereby improving the chance of full clinical beneﬁt from therapy
(Cochrane, 1992; Cochrane et al., 1999). Furthermore, reduced
time spent with patients will decrease the burden of healthcare
practitioners, with a direct impact on the expense for drug
administration.
The omalizumab dosing table revision described in this report
allowed the frequency of administration of omalizumab to be
reduced for patients with certain combinations of bodyweight
and baseline IgE level. This report also supports the notion that
in some cases, when there is sufﬁcient validation, i.e. evidence that
a model is predictive of data, that simulation can be used in place
of clinical studies to predict the impact of changes such as in dos-
age and dosage interval.
Using a model created from clinical data and simulation
thereof, we predicted that, for certain patients, doubling the dose
of omalizumab and dosing every 4 weeks instead of every
2 weeks would produce acceptable PK–PD biomarker proﬁles
and would be unlikely to have a clinically signiﬁcant effect on
treatment efﬁcacy or to present signiﬁcant additional safety
concerns.
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pink had omalizumab driving symptom change, cyan free IgE, black omalizumab driving basophil FceRI, which drove symptom change. The simulations were for either the
original dosing table or the revision with doses up to 600 mg q4w. To illustrate better any possible differences, the symptom simulations were for the 6 cells covering 40–
70 kg bodyweight and 300–500 IU/mL baseline IgE, originally licensed for 225 or 300 mg q2w, now revised to 450 and 600 mg q4w. Within each panel the q4w dosing is that
with the slightly larger peak-to-trough variation.
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ous studies (Lowe et al., 2009; Lowe and Renard, 2011) has been
shown to be predictive for observed clinical data including Cmax
and Cmin (i.e. Ctrough) for omalizumab, Cmin and Ctrough for free IgE,
irrespective of the dose, regimen and patient factors such as body-
weight and baseline IgE. The model is useful for aiding the assess-
ment and interpretation of patient safety and efﬁcacy. The results
of simulations show that the model has high predictivity for oma-
lizumab concentrations and free IgE levels in healthy subjects and
patients with asthma, and that a reduced efﬁcacy when using the
revised dosing table versus the existing dosing table would not
be expected. In theory, ﬂuctuations in response could follow a
switch from every 2 weeks to every 4 weeks dosing regimen; how-
ever, calculations suggest that this is unlikely to be observed in
practice.The revised dosing regimen will increase peak serum concen-
trations of omalizumab, as the dose will be doubled but be given
every 4 weeks. Once steady-state is reached, however, the increase
in exposure will only be, on average, 10%, even for patients exposed
to the highest concentrations at the upper 97.5th percentile. The
peak serum concentrations are tolerable; peak and average drug
exposure for the revised cells will, in any case, be lower than in
those patients already needing to receive 600 mg doses every
2 weeks due to their higher baseline IgE or larger bodyweights.
Similarly, the PD effects on free IgE will be such that there will
be slightly increased suppression in the ﬁrst part of the dosing
cycle; the average suppression will remain the same.
It might be argued that the PK–PD model presented herein only
relates to free IgE; other potential mechanisms of action, such as
reduction of FceRI on relevant cells (including mast cells and
76 P.J. Lowe et al. / Regulatory Toxicology and Pharmacology 71 (2015) 68–77basophilic granulocytes), were not measured. Statements regard-
ing clinical efﬁcacy based on IgE suppression alone may not be suf-
ﬁciently reliable. As a counterpoint, it is possible to explore the
implications of potential mechanisms of action by representing
them as PK–PD models and ﬁtting them to symptom data. If the
models can adequately describe said data, one can then, by simu-
lation, demonstrate the clinical signiﬁcance of changes in posology.
Three hypotheses were investigated.
In the ﬁrst, omalizumab is responsible for the improvements in
the signs and symptoms of asthma. A delay between exposure to
serum omalizumab and its effects on symptoms was allowed by
having omalizumab working indirectly by affecting undeﬁned
(latent) processes responsible for the production of symptoms.
This is the commonly described indirect response model which
combines all elements of the causal chain between a drug and
downstream responses into a single input–output process with
some factors promoting and others removing or healing the symp-
toms (Derendorf and Meibohm, 1999). This model is the most
straightforward and does not invoke any deeper mechanisms other
than the fact that omalizumab is carried from the injection site to
its site of action by the blood, which is sampled.
In the second hypothesis, an element of the mechanism of
action was included by stating that omalizumab works by binding
and capturing IgE to form complexes, thereby lowering free
(unbound) IgE concentrations. It is the free IgE that is responsible
for the production of factors responsible for the asthma symptoms;
therefore suppression of this will improve symptoms.
In the third hypothesis, omalizumab works not via free IgE per
se, but by inhibiting the expression of cellular Fce receptors. The
cellular receptors are then responsible for the production of symp-
toms; down-regulating these will therefore allow healing. Since no
cellular FceRI data were directly available from in-house studies,
the data from MacGlashan 1997 was digitized and a model curve
ﬁtted (MacGlashan et al., 1997).
The results from the three models demonstrated that each of
the three hypotheses have the ability to explain the observed
changes in symptoms equally well, within the range of variation
in the observed mean data over time. Both the omalizumab and
free IgE hypotheses estimated a 20–22 day mean response time
between exposure to omalizumab or suppression of free IgE and
symptom changes. For the FceRI hypothesis, the system response
was split into two: the ﬁrst a 4-day mean response time to
down-regulate basophil FceRI, then 14 days for the symptoms to
respond to changes in FceRI. The end result was the same as the
other two hypotheses.
Asthma symptoms take a minimum of 12–16 weeks to stabilize
following the introduction of omalizumab, i.e. 4–5 of the above
described ‘mean response times’, just as it takes 4–5 pharmacoki-
netic half-lives for a drug to reach steady-state. In general, the
longer it takes a biological system to respond, the less likely it is
that changes in the regimen would inﬂuence that response
(Slavin et al., 2009). Hence, changing the omalizumab dosing regi-
men from every 2 weeks to every 4 weeks will not affect its
efﬁcacy.
On average, levels of omalizumab–IgE complexes will also be
unaffected by the revised dosing schedule. Omalizumab is dosed
in excess of IgE; there can be no more complexes formed than
there is available IgE in the body. Given that omalizumab sup-
presses free IgE 100-fold, the main contributor to total IgE are
the omalizumab–IgE complexes. During omalizumab therapy, total
IgE initially increases, and then reaches a plateau. Higher doses of
omalizumab cannot further increase total IgE to any discernable
extent, but will further suppress free IgE (Fig. 7a).
The clinical trials and postmarketing database showed that the
adverse event proﬁles of patients with the highest serum concen-
trations of omalizumab were generally similar to those in patientsreceiving lower doses, suggesting that safety would not be com-
promised using the higher doses every 4 weeks. The analyzed data-
set did not identify any speciﬁc, more frequent or serious adverse
events that may be attributable to the use of high doses of oma-
lizumab. There is no evidence that anaphylaxis is a dose- or con-
centration-dependent AE. Hence, the incidence of anaphylaxis is
not expected to increase with the revised dosing regimen as com-
pared with the previously reported incidence of 0.2% (Limb et al.,
2007).
5. Conclusions
PK–PD modeling and simulation, together with pooled analyses
of safety data, suggests that those patients currently receiving
omalizumab at doses of 225 or 300 mg every 2 weeks will be able
to switch to omalizumab 450 and 600 mg, respectively, every
4 weeks, without compromising safety or efﬁcacy. Whether the
sequence of actions is driven by omalizumab arriving at the effec-
tor site from the blood, or is indirect via free IgE suppression, or via
inhibition of effector cells, or even combinations of these mecha-
nisms, is immaterial to the point in question that 300 mg q2w
and 600 mg q4w will translate to comparable steady-state concen-
trations of drug, the same steady-state concentrations of free IgE
and the same steady-state downstream effector cell desensitiza-
tion, and hence the same clinical response. The new dosing regi-
men will simplify posologies for eligible patients, may improve
patient and healthcare provider convenience for the treatment
and the associated direct and indirect expenses.
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